Skip to main
BAX
BAX logo

Baxter (BAX) Stock Forecast & Price Target

Baxter (BAX) Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 11%
Buy 22%
Hold 56%
Sell 11%
Strong Sell 0%

Bulls say

Baxter International's Healthcare Systems & Technologies segment demonstrated positive sales growth, with increases of approximately 6% and 2% year-over-year in 1Q25 and 2Q25, respectively, and projected growth of about 4% and 2% for 3Q25 and 4Q25, which suggests a recovering demand in the medical equipment sector. Additionally, the company's strategic pricing initiatives are expected to contribute approximately 100 basis points to sales growth in both 2024 and 2025, further supporting its financial performance. Despite concerns regarding the sustainability of this growth as comparisons normalize in 2026, the company's diversified portfolio and recent acquisitions indicate a solid foundation for potential future success.

Bears say

Baxter International experienced a disappointing second quarter in 2025, with sales, margins, and earnings per share (EPS) all falling below consensus expectations. The company has faced challenges during the 2021-2023 period, marked by both external factors and internal operational missteps, resulting in mixed quarterly performances and revisions to negative guidance. Furthermore, sales softness, along with manufacturing inefficiencies and an unfavorable product mix, contributed to gross margins of 40.7%, which missed consensus estimates of 42.7% and 42.6%, while operating margins at 15.1% also fell short by over 100 basis points.

Baxter (BAX) has been analyzed by 9 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 22% recommend Buy, 56% suggest Holding, 11% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Baxter and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Baxter (BAX) Forecast

Analysts have given Baxter (BAX) a Hold based on their latest research and market trends.

According to 9 analysts, Baxter (BAX) has a Hold consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Baxter (BAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.